

Applicants: Stephen P. Goff, et al.  
Serial No.: NOT YET KNOWN  
Filed : December 6, 2001  
Page 2

complex between the p66 subunit polypeptide and the  
p51 subunit polypeptide of HIV-1 reverse  
transcriptase.--

--103. (Amended) A method of inhibiting the growth of HIV-1  
comprising administering the compound of claim 66,  
alone or in combination with a known NNRTI, in an  
amount effective to inhibit HIV-1.--

**Remarks:**

Claims 1-108 were pending in the subject application. Applicants  
have hereinabove canceled claims 1-3, 5-60 and 62-64 without  
prejudice or disclaimer to their right to pursue the subject  
matter of these claims in a later-filed application and amended  
claims 82, 87 and 103. This amendment does not involve any issue  
of new matter. Therefore entry of this amendment is respectfully  
requested such that claims 4, 61 and 65-108 will be pending.

If a telephone interview would be of assistance in advancing  
prosecution of the subject application, applicants' undersigned  
attorneys invites the Examiner to telephone either of them at the  
number provided below.

Applicants: Stephen P. Goff, et al.  
Serial No.: NOT YET KNOWN  
Filed : December 6, 2001  
Page 3

No fee, in addition to the enclosed \$1208.00 fee, which includes the \$710.00 filing fee and the \$468.00 fee for additional claims, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Spencer H. Schneider  
Registration No. 45,923  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

Applicants: Stephen P. Goff, et al.  
Serial No.: NOT YET KNOWN  
Filed : December 6, 2001  
Page 4

Exhibit A

- 82. (Amended) A composition comprising [at least one] the compound of [any one of] claim[s] 66[-81] and a pharmaceutically acceptable carrier.--
- 87. (Amended) A method of enhancing formation of a complex between a p66 subunit polypeptide of HIV-1 reverse transcriptase and a p51 subunit polypeptide of reverse transcriptase, which comprises contacting the p66 and p51 subunits with an effective amount of [at least one] the compound of [any one of] claim[s] 66[-81], so as to thereby enhance formation of a complex between the p66 subunit polypeptide and the p51 subunit polypeptide of HIV-1 reverse transcriptase.--
- 103. (Amended) A method of inhibiting the growth of HIV-1 comprising administering [at least one] the compound of [any one of] claim[s] 66[-81], alone or in combination with a known NNRTI, in an amount effective to inhibit HIV-1.--